Posterior Scleritis

  • Sophia Zagora
  • Denis Wakefield
  • Peter McCluskeyEmail author
Part of the Retina Atlas book series (RA)


Scleritis is a severe, potentially sight-threatening form of ocular inflammation characterized by oedema of episcleral and scleral tissues with involvement of the deep episcleral vascular plexus (Beardsley et al. 2013; Artifoni et al. 2014) (Fig. 14.1). Scleritis may be associated with infection, systemic vasculitis, autoimmune disease or be idiopathic in nature. A careful history, physical and ocular examination and targeted investigations are essential as scleritis may be the presenting feature of a potentially life-threatening systemic vasculitis or infectious disease (Albini et al. 2005a; Beardsley et al. 2013). Scleritis remains a therapeutic challenge, particularly in patients with severe ocular inflammation, a systemic vasculitis or associated autoimmune disorder.


  1. Accorinti M, Abbouda A, Gilardi M, Zito R, Iannetti L. Cytomegalovirus-related Scleritis. Ocul Immunol Inflamm. 2013;21:413–5.CrossRefGoogle Scholar
  2. Akpek E, Thorne J, Qazi F, Do D, Jabs D. Evaluation of patients with scleritis for systemic disease. Ophthalmology. 2004;111:501–6.CrossRefGoogle Scholar
  3. Albini TA, Rao NA, Smith RE. The diagnosis and management of anterior scleritis. Int Ophthalmol Clin. 2005a;45:191–204.CrossRefGoogle Scholar
  4. Albini TA, Zamir E, Read RW, Smith RE, See RF, Rao NA. Evaluation of subconjunctival triamcinolone for nonnecrotizing anterior scleritis. Ophthalmology. 2005b;112:1814–20.CrossRefGoogle Scholar
  5. Anshu A, Chee SP. Posterior scleritis and its association with HLA B27 haplotype. Ophthalmologica. 2007;221:275–8.CrossRefGoogle Scholar
  6. Artifoni M, Rothschild PR, Brezin A, Guillevin L, Puechal X. Ocular inflammatory diseases associated with rheumatoid arthritis. Nat Rev Rheumatol. 2014;10:108–16.CrossRefGoogle Scholar
  7. Beardsley RM, Suhler EB, Rosenbum JT. Pharmacotherapy of scleritis: current paradigms and future directions. Expert Opin Pharmacother. 2013;14:411–24.CrossRefGoogle Scholar
  8. Berchicci L, Miserocchi E, Di Nicola M, La Spina C, Bandello F, Modorati G. Clinical features of patients with episcleritis and scleritis in an Italian tertiary care referral center. Eur J Ophthalmol. 2014;24:293–8.CrossRefGoogle Scholar
  9. Bernauer W, Pleisch B, Brunner M. Five-year outcome in immune-mediated scleritis. Graefes Arch Clin Exp Ophthalmol. 2014;252:1477–81.CrossRefGoogle Scholar
  10. Bhat PV, Jakobiev FA, Kurbanyan K, Zhao T, Foster CS. Chronic herpes simplex scleritis: characterization of 9 cases of an underrecognized clinical entity. Am J Ophthalmol. 2009;148:779–89.CrossRefGoogle Scholar
  11. Biswas J, Aparna AC, Annamalai R, Vaijayanthi K, Bagyalakshmi R. Tuberculous scleritis in a patient with rheumatoid arthritis. Ocul Immunol Inflamm. 2012;20:49–52.CrossRefGoogle Scholar
  12. Brouwer E, Huitema MG, Mulder AH, Heeringa P, Van Goor H, Tervaert JW, Weening JJ, Kallenberg CG. Neutrophil activation in vitro and in vivo in Wegener’s granulomatosis. Kidney Int. 1994;45:1120–31.CrossRefGoogle Scholar
  13. Charkoudian LD, Ying GS, Pujari SS, Gangaputra S, Thorne JE, Foster CS, et al. High-dose intravenous corticosteroids for ocular inflammatory diseases. Ocul Immunol Inflamm. 2012;20:91–9.CrossRefGoogle Scholar
  14. Cunningham ET, McCluskey P, Pavesio C, Wakefield D, Zierhut M. Scleritis. Ocul Immunol Inflamm. 2016;24:2–5.CrossRefGoogle Scholar
  15. De Fidelix TS, Vieira LA, De Freitas D, Trevisani VF. Biologic therapy for refractory scleritis: a new treatment perspective. Int Ophthalmol. 2015;35:903–12.CrossRefGoogle Scholar
  16. Di Girolamo N, Atik A, McCluskey PJ, Wakefield D. Matrix metalloproteinases and their inhibitors in squamous cell carcinoma of the conjunctiva. Ocul Surf. 2013;11:193–205.CrossRefGoogle Scholar
  17. Gonzalez-Gonzalez LA, Molina-Prat N, Doctor P, Tauber J, Sainz de la Maza M, Foster CS. Clinical features and presentation of posterior scleritis: a report of 31 cases. Ocul Immunol Inflamm. 2014;22:203–7.CrossRefGoogle Scholar
  18. Gonzalez-Lopez JJ, Lavric A, Dutta Majumder P, Bansal N, Biswas J, Pavesio C, et al. Bilateral posterior scleritis: analysis of 18 cases from a large cohort of posterior scleritis. Ocul Immunol Inflamm. 2016;24:16–23.CrossRefGoogle Scholar
  19. Hakin KN, Watson PG. Systemic associations of scleritis. Int Ophthalmol Clin. 1991;31:111–29.CrossRefGoogle Scholar
  20. Harper L, Cockwell P, Adu D, Savage CO. Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int. 2001;59:1729–38.CrossRefGoogle Scholar
  21. Helm CJ, Holland GN. Ocular tuberculosis. Surv Ophthalmol. 1993;38:229–56.CrossRefGoogle Scholar
  22. Hoang-Xaun T, Foster CS, Rice BA. Scleritis in relapsing polychondritis. Response to therapy. Ophthalmology. 1990;97:892–8.CrossRefGoogle Scholar
  23. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med. 1992;116:488–98.CrossRefGoogle Scholar
  24. Jabs D, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130:469–76.CrossRefGoogle Scholar
  25. Jain V, Garg P, Sharma S. Microbial scleritis-experience from a developing country. Eye. 2009;23:255–61.CrossRefGoogle Scholar
  26. Keino H, Watanabe T, Taki W, Nakashima C, Okada AA. Clinical features and visual outcomes of Japanese patients with scleritis. Br J Ophthalmol. 2010;94:1459–63.CrossRefGoogle Scholar
  27. Lavric A, Gonzalez-Lopez JJ, Majumder PD, Bansal N, Biswas J, Pavesio C, et al. Posterior scleritis: analysis of epidemiology, clinical factors, and risk of recurrence in a cohort of 114 patients. Ocul Immunol Inflamm. 2016;24:6–15.CrossRefGoogle Scholar
  28. Liesegang TJ. Diagnosis and therapy of herpes zoster ophthalmicus. Ophthalmology. 1991;98:1216–29.CrossRefGoogle Scholar
  29. Lin CP, Shih MH, Tsai MC. Clinical experiences of infectious scleral ulceration: a complication of pterygium operation. Br J Ophthalmol. 1997;81:980–3.CrossRefGoogle Scholar
  30. McCluskey P, Wakefield D. Prediction of response to treatment in patients with scleritis using a standardised scoring system. Aust N Z J Ophthalmol. 1991;19:211–5.CrossRefGoogle Scholar
  31. McCluskey PJ, Watson PG, Lightman S, Haybittle J, Restori M, Branley M. Posterior scleritis: clinical features, systemic associations, and outcome in a large series of patients. Ophthalmology. 1999;106:2380–6.CrossRefGoogle Scholar
  32. Okhravi N, Odufuwa B, McCluskey P, Lightman S. Scleritis. Surv Ophthalmol. 2005;50:351–63.CrossRefGoogle Scholar
  33. Raiji VR, Palestine AG, Parver DL. Scleritis and systemic disease association in a community-based referral practice. Am J Ophthalmol. 2009;148:946–50.CrossRefGoogle Scholar
  34. Reinprayoon U, Sitthanon S, Kasetsuwan N, Chongthaleong A. Bacteriological findings and antimicrobial susceptibility pattern of isolated pathogens from visual threatening ocular infections. J Med Assoc Thail. 2015;98:S70–6.Google Scholar
  35. Riono WP, Hidayat AA, Rao NA. Scleritis: a clinicopathologic study of 55 cases. Ophthalmology. 1999;106:1328–33.CrossRefGoogle Scholar
  36. Sainz de la Maza M, Jabbur NS, Foster CS. An analysis of therapeutic decision for scleritis. Ophthalmology. 1993;100:1372–6.CrossRefGoogle Scholar
  37. Sainz de la Maza M, Foster CS, Jabbur NS. Scleritis associated with rheumatoid arthritis and with other systemic immune-mediated diseases. Ophthalmology. 1994;101:1281–6; discussion 1287-8.CrossRefGoogle Scholar
  38. Sainz de la Maza M, Foster CS, Jabbur NS. Scleritis associated with systemic vasculitic diseases. Ophthalmology. 1995;102:687–92.CrossRefGoogle Scholar
  39. Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS. Scleritis therapy. Ophthalmology. 2012;119:51–8.CrossRefGoogle Scholar
  40. Wakefield D, Mccluskey P, Wildner G, Thurau S, Carr G, Chee SP, Forrester J, Dick A, Hudson B, Lightman S, Smith J, Tugal-Tutkun I, Pre-Treatment Assessment Review Panel. Inflammatory eye disease: pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: recommendations from an expert committee. Autoimmun Rev. 2017;16:213–22.CrossRefGoogle Scholar
  41. Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. 1976;60:163–91.CrossRefGoogle Scholar
  42. Watson P, Romano A. The impact of new methods of investigation and treatment on the understanding of the pathology of scleral inflammation. Eye (Lond). 2014;28:915–30.CrossRefGoogle Scholar
  43. Wieringa WG, Wieringa JE, ten Dam-van Loon NH, Los LI. Visual outcome, treatment results, and prognostic factors in patients with scleritis. Ophthalmology. 2013;120:379–86.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  • Sophia Zagora
    • 1
    • 2
  • Denis Wakefield
    • 3
  • Peter McCluskey
    • 1
    • 2
    Email author
  1. 1.Sydney Eye HospitalSydneyAustralia
  2. 2.Save Sight Institute, Discipline of Ophthalmology, Sydney Medical School, University of SydneySydneyAustralia
  3. 3.School of Medical SciencesUniversity of NSWSydneyAustralia

Personalised recommendations